72.60p-1.20 (-1.63%)21 May 2024, 16:35
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Niox Group PLC Fundamentals

Company NameNiox Group PLCLast Updated2024-05-21
IndustryMedical DevicesSectorHealthcare
Shares in Issue424.045 mMarket Cap£307.86 m
PE Ratio34.98Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£0.02EPS Growth (%)-0.33
PEG0DPS Growth (%)0
Debt Ratio0.0120Debt Equity Ratio0.0060
Asset Equity Ratio1.0919Cash Equity Ratio0.2375
Quick Ratio3.9861Current Ratio4.65
Price To Book Value3.6738ROCE0

Niox Group PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Niox Group PLC Company Financials

Tangible Assets£1.40 m£1.10 m£1.40 m
Intangible Assets£32.80 m£37.10 m£42.10 m
Total Fixed Assets£58.00 m£67.10 m£66.60 m
Stocks£4.80 m£4.10 m£2.70 m
Debtors£8.80 m£7.90 m£4.50 m
Cash & Equivalents£19.90 m£19.40 m£12.60 m
Other Assets000
Total Assets£91.50 m£98.50 m£86.40 m
Creditors within 1 year£7.20 m£9.20 m£10.80 m
Creditors after 1 year£500,000.00£7.40 m£8.80 m
Other Liabilities000
Total Liabilities£7.70 m£16.60 m£19.60 m
Net assets£83.80 m£81.90 m£66.80 m
Called up share capital£300,000.00£300,000.00£300,000.00
Share Premium£100,000.00£640.30 m£640.30 m
Profit / Loss£4.10 m£10.50 m-£2.10 m
Other Equity£83.80 m£81.90 m£66.80 m
Preference & Minorities000
Total Capital Employed£83.80 m£81.90 m£66.80 m
Debt Ratio£0.01£0.00£0.01
Assets / Equity1.09191.09191.0919
Cash / Equity0.23750.23750.2375
Cash Flow202320222021
Cash from operating activities£11.60 m£6.70 m£1.40 m
Cashflow before financing£1.10 m£6.20 m£5.50 m
Increase in Cash£800,000.00£6.10 m£5.30 m
Turnover£36.80 m£31.30 m£27.90 m
Cost of sales£10.30 m£9.10 m£8.90 m
Gross Profit£26.50 m£22.20 m£19.00 m
Operating Profit£4.60 m£1.80 m-£4.30 m
Pre-Tax profit£4.10 m£10.50 m-£2.10 m

Niox Group PLC Company Background

ActivitiesNIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the UnitedStates, the United Kingdom, and the Rest of the world.
Latest Interim Date26 Sep 2023
Latest Fiscal Year End Date26 Mar 2024

Niox Group PLC Directors

2024-04-29Mr. Michael Roy David RollerExecutive Director,Chief Financial Officer
2024-03-26Mr. Garry Watts MBENon-Executive Director,Senior Independent Director
2019-12-05Dr. Francesco GranataNon-Executive Director,Chairman
2024-04-29Mr. Ian Roy JohnsonExecutive Director,Chairman
2020-01-09Mr. Julien Fabrice Cotta Executive Director,Chief Financial Officer and Company Secretary
2019-12-26Mr. Steven Charles Andrew HarrisExecutive Director,Chief Executive Officer
2017-05-26Mr. Charles Stuart Webb Swingland Non-Executive Director
2016-12-16Ms. Cathrin PettyNon-Executive Director
2017-06-05Dr. Jean-Jacques GaraudNon-Executive Director
2017-05-26Dr. Timothy Henry CornNon-Executive Director
2019-08-30Dr. Rod HafnerExecutive Director,Senior Vice President, RandD
2024-04-03Mr. Jonathan Charles EmmsExecutive Director,Chief Operating Officer
2024-03-26Mr. Nicholas Harwood Bertram Mills Non-Executive Director

Niox Group PLC Contact Details

Company NameNIOX Group PLC
AddressMagdalen Centre, Robert Robinson Avenue, Northbrook House, Oxford Science Park, Oxford, OX4 4GA
Telephone+44 1865405560

Niox Group PLC Advisors

StockbrokerNumis Securities Limited
Phone+44 2072601000
Fax+44 2072601001
Remuneration ConsultantNew Bridge Street
Phone+44 2070868000
Fax+44 2076211511
StockbrokerJ.P. Morgan Cazenove Ltd
Phone+44 2077424000
Financial PR AdviserFTI Consulting Inc
Phone+44 2037271000
Fax+44 2037271007
SolicitorAllen & Overy LLP
Phone+44 2030880000
Fax+44 207339999
AuditorPricewaterhouseCoopers LLP
Phone+44 2075835000
Fax+44 2078224652
RegistrarEquiniti Limited